UTHR Stock Analysis: United Therapeutics | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 23.597m USD | 12M Return: 88.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 281M
EPS Trend: 96.7%
Qual. Beats: -1
Rev. Trend: 97.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
United Therapeutics Corporation (NASDAQ: UTHR) is a Silver Spring, Maryland-based biotechnology company founded in 1996 that develops and commercializes therapies for chronic and life-threatening diseases. Its commercial portfolio is anchored in pulmonary arterial hypertension (PAH), an orphan disease market, with products including Tyvaso DPI and Nebulized Tyvaso (inhaled treprostinil), Remodulin injection, Orenitram tablets, and Adcirca. The company also markets Unituxin for high-risk neuroblastoma and sells the Remunity Pump system for subcutaneous Remodulin delivery.
The company has a late-stage pipeline that includes the RemunityPRO Pump and Ralinepag (an oral selective IP receptor agonist) for PAH, plus an expanded use of Nebulized Tyvaso in idiopathic pulmonary fibrosis. United Therapeutics has also invested in a long-term organ transplantation platform, pursuing development-stage xenografts and regenerative medicine products such as UKidney, UHeart, and miroliver, as well as preclinical lung-transplant technologies like EVLP/CLES.
United Therapeutics has historically supplemented its internal R&D with licensing and collaboration agreements, including partnerships with DEKA Research & Development, MannKind Corporation, and Arena Pharmaceuticals. As a large-cap biotechnology issuer within the Health Care sector, the companys revenue model depends on a concentrated set of specialty therapies protected by regulatory exclusivity, with growth tied to label expansions, new product launches, and the longer-term potential of its xenotransplantation program.
- Tyvaso DPI sales accelerate with PH-ILD label expansion
- Xenotransplantation kidney and heart programs advance clinical timelines
- Active share repurchase program supports earnings per share growth
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 0.57 > 1.0 |
| NWC/Revenue: 71.70% < 20% (prev 107.5%; Δ -35.78% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.56b > Net Income 1.29b |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 4.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.2m) vs 12m ago -2.88% < -2% |
| Gross Margin: 86.58% > 18% (prev 89.00%; Δ -2.42% > 0.5%) |
| Asset Turnover: 43.85% > 50% (prev 38.66%; Δ 5.18% > 0%) |
| Interest Coverage Ratio: 99.09 > 6 (EBIT TTM 1.63b / Interest Expense TTM 16.4m) |
| A: 0.34 (Total Current Assets 2.87b - Total Current Liabilities 599.1m) / Total Assets 6.71b |
| B: 1.32 (Retained Earnings 8.83b / Total Assets 6.71b) |
| C: 0.22 (EBIT TTM 1.63b / Avg Total Assets 7.23b) |
| D: 7.26 (Book Value of Equity 5.90b / Total Liabilities 813.1m) |
| Altman-Z'' = 15.64 = AAA |
| DSRI: 0.92 (Receivables 312.0m/322.0m, Revenue 3.17b/2.99b) |
| GMI: 1.03 (GM 89.00% / 86.58%) |
| AQI: 0.92 (AQ_t 0.30 / AQ_t-1 0.32) |
| SGI: 1.06 (Revenue 3.17b / 2.99b) |
| TATA: -0.04 (NI 1.29b - CFO 1.56b) / TA 6.71b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of July 04, 2026, the stock is trading at USD 555.91 with a total of 534,400 shares traded. Over the past week, the price has changed by +2.30%, over one month by +1.17%, over three months by -0.67% and over the past year by +88.77%.
Current recommended Stop Loss: 522.70 (which is 6% or 2.5 ATR below the current price).
United Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy UTHR.
- StrongBuy: 9
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 665.2 | 19.7% |
P/E Trailing = 20.5588
P/E Forward = 20.5339
P/S = 7.4442
P/B = 3.9367
P/EG = 2.2213
Revenue TTM = 3.17b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.71b USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 21.4b USD (23.6b + (null Debt) - CCE 2.15b)
Interest Coverage Ratio = 99.09 (Ebit TTM 1.63b / Interest Expense TTM 16.4m)
EV/FCF = 21.09x (Enterprise Value 21.4b / FCF TTM 1.02b)
FCF Yield = 4.74% (FCF TTM 1.02b / Enterprise Value 21.4b)
FCF Margin = 32.08% (FCF TTM 1.02b / Revenue TTM 3.17b)
Net Margin = 40.61% (Net Income TTM 1.29b / Revenue TTM 3.17b)
Gross Margin = 86.58% ((Revenue TTM 3.17b - Cost of Revenue TTM 425.3m) / Revenue TTM)
Gross Margin QoQ = 82.93% (prev 86.91%)
Tobins Q-Ratio = 3.19 (Enterprise Value 21.4b / Total Assets 6.71b)
Interest Expense / Debt = unknown (Interest Expense 16.4m / Debt none)
Taxrate = 19.97% (321.3m / 1.61b)
NOPAT = 1.30b (EBIT 1.63b * (1 - 19.97%))
Current Ratio = 4.79 (Total Current Assets 2.87b / Total Current Liabilities 599.1m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 1.71b)
Debt / FCF = unknown (Net Debt none / FCF TTM 1.02b)
Total Stockholder Equity = 6.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.81% (Net Income 1.29b / Total Assets 6.71b)
RoE = 19.24% (Net Income TTM 1.29b / Total Stockholder Equity 6.69b)
RoCE = 26.58% (EBIT 1.63b / Capital Employed (Total Assets 6.71b - Current Liab 599.1m))
RoIC = 21.83% (NOPAT 1.30b / Invested Capital 5.96b)
WACC = 7.86% (E(23.6b)/V(23.6b) * Re(7.86%) + (debt-free company))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -2.35%
[DCF] Terminal Value 73.98% ; FCFF base≈1.06b ; Y1≈977.3m ; Y5≈870.2m
[DCF] Fair Price = 325.2 (EV 13.8b - Net Debt 0.0 = Equity 13.8b / Shares 42.4m; r=8.35% [WACC [floored]]; 5y FCF grow -9.90% → 2.50% )
EPS Correlation: 96.67 | EPS CAGR: 18.65% | SUE: -2.02 | # QB: -1
Revenue Correlation: 97.39 | Revenue CAGR: 17.18% | SUE: -0.51 | # QB: 0
EPS current Quarter (2026-06-30): EPS=6.86 | Chg30d=-1.37% | Revisions=+7% | Analysts=12
EPS next Quarter (2026-09-30): EPS=7.03 | Chg30d=-1.42% | Revisions=-7% | Analysts=12
EPS current Year (2026-12-31): EPS=27.06 | Chg30d=-0.91% | Revisions=-53% | GrowthEPS=-2.9% | GrowthRev=+2.0%
EPS next Year (2027-12-31): EPS=31.61 | Chg30d=-0.03% | Revisions=-13% | GrowthEPS=+16.8% | GrowthRev=+14.1%
[Analyst] Revisions Ratio: -20% (up=18, down=28)